Chandigarh, 14.06.25-- The final day of PGIVAC 2025 focused on the latest developments in vaccine science and delivery across all age groups, from infancy to adulthood, under the theme “Update on Current and New Vaccines.” The first plenary, led by Dr. Chandrakant Lahariya, emphasized the life-course approach to immunization, stressing the need to protect health at every age. Dr. Suneela Garg followed with an urgent call for stronger adult immunization strategies, while Dr. Kamini Walia connected vaccination to combating antimicrobial resistance, reinforcing the broader public health implications of vaccines. Dr. Lalit Sankhe and Dr. Muralidhar Tambe shared practical insights from adult immunization clinics, and Dr. Veena Kamath provided an update on the adult pneumococcal vaccine. Dr. Parvinder Kaur Chawla, Dr. Ashish Bhalla, and Dr. Rashmi Bagga gave updates on shingles, meningococcal, cholera, hepatitis A, HPV, and TB vaccines. Dr. Swayampragyan Parida closed the pre-lunch session with information on travel vaccines. The afternoon session turned to pediatric immunization. Dr. Sanjay Verma and Dr. Unmesh Upadhyay reviewed licensed vaccines in children and adolescents, including pneumococcal, hexavalent, typhoid, and RSV vaccines. Dr. Omesh Bharti, Dr. Harpreet Singh, and Dr. Jerome Kim then presented updates on rabies, dengue, malaria, and HIV/AIDS vaccines. Dr. Vivek Sagar discussed progress on the Group A Streptococcus vaccine, while Dr. Ravindra Khaiwal highlighted the impact of climate change on immunization programs. Dr. Tarun Saluja concluded the technical sessions with a forward-looking discussion on leveraging public-private partnerships for accelerating vaccine R&D in low- and middle-income countries (LMICs). The day ended with a valedictory session, marking the culmination of five days of expert-led discussions and global collaboration at PGIVAC 2025. Dr. Sanjay Jain, Dean Research, PGIMER, distributed the certificates to all the PGIVACers for completing the course. With this impactful finale, PGIVAC 2025 successfully concluded, reinforcing its role as a premier platform for building the next generation of vaccinologists and public health leaders.